DELRAY BEACH, Fla., Dec. 15, 2025 /PRNewswire/ -- According to MarketsandMarkets, the US In Vitro Diagnostics Market is projected to grow from about USD 37.43 Billion in 2025 to USD 57.18 billion by 2031, at a CAGR of 7.3%.
Browse through 91 market data tables and 44 figures spread across 200 Pages and in-depth TOC on " US In Vitro Diagnostics Market - Global Forecast to 2031"
US In Vitro Diagnostics Market Size & Forecast:
- Market Size Available for Years: 2023-2031
- 2025 Market Size: USD 37.43 billion
- 2030 Projected Market Size: USD 57.18 billion
- CAGR (2025-2030): 7.3%
US In Vitro Diagnostics Market Trends & Insights:
- By product & service, the reagents & kits segment is expected to register the highest CAGR of 7.9% during the forecast period.
- By technology, the immunoassays segment accounted for the largest share of 33.5% in 2025.
- By specimen, the blood, serum, and plasma specimens segment is expected to dominate the market, growing at the highest CAGR of 7.9%.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=66290979
Market growth is largely driven by the increasing demand for early disease detection, the rising prevalence of chronic and infectious conditions, the wider adoption of molecular and point-of-care diagnostics, continuous advancements in testing technologies, and ongoing investments in laboratory automation and healthcare infrastructure.
In August 2025, Thermo Fisher Scientific Inc. (US) opened a new, innovative Manufacturing Center of Excellence in the US. This carbon-neutral facility is capable of producing a minimum of 40 million laboratory pipette tips each week.
By specimens, the blood, serum, and plasma specimens segment held the largest share of the US in vitro diagnostics market.
the US in vitro diagnostics market is segmented into blood, serum, and plasma specimens, saliva specimens, urine specimens, and other specimens. Among these, the blood, serum, and plasma specimens segment held the largest market share in 2025, driven by the extensive use of blood-based testing across a wide range of diagnostic applications, including infectious diseases, chronic disease monitoring, and oncology. The high clinical reliability, standardized collection procedures, and compatibility with multiple diagnostic platforms further support the dominance of this specimen category.
Request Sample Pages@https://www.marketsandmarkets.com/requestsampleNew.asp?id=66290979
By site of testing, the laboratory tests segment held the largest share of the US in vitro diagnostics market
the US in vitro diagnostics market is segmented into laboratory tests and point-of-care tests. In 2025, the laboratory tests segment accounted for the largest market share, supported by the widespread presence of centralized and hospital-based laboratories, high testing volumes, and extensive use of automated, high-throughput diagnostic systems. The segment enables comprehensive testing across infectious diseases, oncology, cardiology, and chronic conditions, delivering consistent accuracy and standardized quality. Continued investment in laboratory automation and workflow optimization is further supporting the growth of laboratory testing across the US.
Inquire Before Buying@https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=66290979
Top Companies in US In Vitro Diagnostics Market:
The Top Companies in US In Vitro Diagnostics Market include Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Becton, Dickinson and Company (US), bioMérieux (France), Illumina, Inc. (US), QuidelOrtho Corporation (US), and Hologic, Inc. (US).
Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting
Related Reports:
In Vitro Diagnostics Market - Global Forecast to 2030
Molecular Diagnostics Market - Global Forecast to 2030
IVD Quality Control Market - Global Forecast to 2030
Immunoassay Market - Global Forecast to 2030
Point of Care Diagnostics Market - Global Forecast to 2029
About MarketsandMarkets
MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/us-in-vitro-diagnostics-market-worth-57-18-billion-by-2031--marketsandmarkets-302642140.html
